Former FDA chief challenges agency to bar certain ultraprocessed food ingredients
In a petition filed Wednesday, the former FDA commissioner, Dr. David Kessler, argued that the agency has the authority to declare that certain sweeteners, refined flours and other additives are not 'generally recognized as safe.' Removing that designation, known as GRAS, would force makers of ultraprocessed foods to remove products from the market and reformulate recipes — or try to prove that those ingredients are not harmful.
It would be a sweeping change to the food industry and a significant shift in the Trump administration's MAHA strategy. So far, US Health and Human Services Secretary Robert F. Kennedy Jr. has relied on popular food brands to volunteer to remove artificial dyes and other additives from their products.
'Kessler has given the FDA a way to define the vast majority of ultra-processed foods. In doing so, he has handed RFK Jr a huge gift on the path to regulating these products. It's just what MAHA has asked for. I hope they take it seriously,' Marion Nestle, the Paulette Goddard professor emerita of nutrition, food studies and public health at New York University, said in an email.
Kessler proposed that companies have 12 months to submit a petition to keep those food additives in their products and then go on to prove they are safe.
'It's a very appropriate, worthy step to shift the burden of proof where it belongs and have the industry meet that burden, or stop using the substances.' said Michael Taylor, a former FDA food regulator and current co-chair of the nonprofit STOP Foodborne Illness. 'It's using the GRAS tool to really drive a serious safety conversation.'
HHS did not respond to a request for comment.
Federal health officials announced last month that they are looking for input on how to define ultraprocessed foods, a first step in eventually setting up new regulations, which could take months to years to establish. Kessler's petition could put pressure on that ultimately lengthy timeline; the agency is required to respond to the request within 180 days.
Kessler, a physician who served as FDA commissioner under presidents Bill Clinton and George H.W. Bush, and advised President Joe Biden during the Covid-19 pandemic, oversaw the agency when it began requiring nutrition labels on food products.
He also spearheaded efforts for FDA to regulate tobacco in the 1990s and sees parallels to that fight.
'What was key in tobacco was finding the regulatory hook,' Kessler told CNN. 'It was about asking the right legal question that would frame the issue.'
That has been the tricky part of setting up any regulatory standards for sugary and starchy foods, he said.
The term ultra processed foods has resonated with the public, he said, but 'it's going to be hard to define, legally, what's in it.'
But there is a pressing need to do that, he argues. The FDA allowed these ingredients under GRAS regulations four decades ago, and rates of obesity, diabetes, and heart disease have climbed in the years since, he wrote in his petition. The argument echoes Kennedy's own case for MAHA reforms to food policy.
A 'brilliant' move on processed foods
The petition focuses on refined flours and starches — which the body breaks down into sugars — that are subjected to food extrusion technology, including wheat, corn, tapioca, oat and potato flour. It also references refined sugars, including corn syrup, corn solids, dextrose, xylose, maltose, and high-fructose corn syrups. Finally, the petition targets any manufactured sugars, flours and starches that contain additives commonly used in today's ultraprocessed foods.
Tackling the issue of too much sugar is a key to better health, experts CNN spoke with agree, but they say the real genius of Kessler's petition is his focus on additives.
'The food industry uses the emulsifiers, the stabilizers, the gels and the rest to make inexpensive, high volume, industrially processed foods,' said Christopher Gardner, director of nutrition studies at the Stanford Prevention Research Center.
'If you take those tools away from industry it's not that foods will taste bad and icky,' Gardner said. 'They won't be as addictive, as flavorful, as tasty — and industry has made these foods as manipulatively flavorful and manipulatively tasty. That's the problem.'
Several food and nutrition experts heralded Kessler's petition as a bold move that would, if enacted by FDA, reshape the food industry.
'This is an important proposal that is based on the true meaning of GRAS, which would exclude the majority of foods on our grocery shelves,' said leading nutrition researcher Dr. Walter Willett, professor of epidemiology and nutrition at Harvard T.H. Chan School of Public Health and professor of medicine at Harvard Medical School in Boston.
The GRAS standard, created in 1958, was originally intended to narrowly apply to commonly used ingredients in the nation's food supply, such as oil, vinegar and baking soda. Manufacturers that used those products could rely on existing research to show their safety but are supposed to file GRAS petitions for newer ingredients like refined sugars.
FDA updated its system in the late 1990s — amid a backlog of petitions for new additives — allowing companies to voluntarily notify the agency that they had determined their ingredients were generally safe.
A 2022 analysis conducted by the Environmental Working Group found that nearly 99% of new chemicals used in food or food packaging since 2000 were green-lit for use not by the FDA but by the food and chemical industry.
During that period, food manufacturers asked the FDA's permission to introduce a new substance only 10 times, according to the analysis.
Barry Popkin, the W. R. Kenan, Jr. Distinguished Professor at the Gillings School of Global Public Health in Chapel Hill, North Carolina, called Kessler's petition 'a brilliant move.'
'Knowing the FDA like he does - he's put industry in a real bind,' Popkin said. 'They have to show that without a reasonable doubt that carbohydrates, along with additives, are healthy, and do not hurt health. And that's next to impossible.
'It's the strongest play a citizen can do to affect our food supply that I've ever seen.'
But Kessler's proposed changes are likely to meet significant pushback from major food brands.
Michael Taylor was FDA's deputy commissioner for foods in 2015 when the agency revoked the GRAS status of partially hydrogenated oils, or trans fats, citing extensive research about their links to risks of heart disease and stroke. The agency gave companies three years to comply and remove those oils from their products.
But at that time, 'the handwriting was on the wall' for industry and many companies had already stopped using those trans fats, Taylor said. 'Obviously the substances that [Kessler] is describing, it's a lot of … highly processed, fine carbohydrates, and a lot of products.'
The petition lands as Trump administration officials, led by Kennedy, prepare to release their second MAHA report. While the MAHA Commission's first dispatch in June singled out potential drivers of chronic illnesses in children — including ingredients in ultraprocessed foods — its second installment is expected to lay out proposed policy changes. The report is due by Tuesday.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
16 minutes ago
- Yahoo
Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills?
Key Points Hims & Hers Health continues to post robust growth. Shares sold off, however, after revenue missed analyst expectations. The stock is still reasonably valued given its growth prospects. 10 stocks we like better than Hims & Hers Health › Hims & Hers Health (NYSE: HIMS) is one of the most volatile stocks on the market at the moment, prone to big swings in either direction. This is true even intraday, as the stock plunged following the company's second-quarter results, only to rally back, only to plunge again. As of this writing, the stock is still trading up more than 130% this year. Let's take a closer look at the most recent earnings results for this telehealth company focused on providing accessible and affordable healthcare solutions for various health and wellness needs, and its prospects. Who knows, you might want to jump in on this somewhat volatile growth stock. Hims saw strong revenue growth in Q2 Hims & Hers continued to deliver outstanding revenue growth in Q2, with sales climbing 73% year over year to $544.8 million. That was toward the high end of its forecast for revenue of $530 million to $550 million, but it missed analyst expectations for revenue of $552 million. Monthly online revenue per subscriber jumped 30% to $74 per month, while the number of subscribers climbed 31% to nearly 2.44 million. The company said that the number of subscribers in both oral weight loss and dermatology grew more than 55% in the quarter. Customers using at least one personalized subscription increased by 89% to 1.5 million, representing more than 60% of the Hims & Hers subscriber base. It said that 70% of new patients who join the platform use a personalized treatment plan, and that the number of subscribers using a personalized treatment plan to treat multiple conditions skyrocketed 170% to more than 500,000. Revenue from GLP-1 weight loss drugs fell from $230 million in Q1 to $190 million in Q2, after Novo Nordisk ended a partnership with the telehealth company. Nonetheless, it still expects to generate $725 million of revenue this year from weight loss drugs, led by oral weight loss products and personalized doses. Hims & Hers continues to spend heavily on marketing to attract new customers. During the quarter, its marketing spending jumped 50% to nearly $218 million. Marketing expenses took up 40% of revenue in the quarter, though that was down from 46% a year ago, so the company continues to see leverage in this area despite the increased spending. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) surged to $82.2 million from $39.3 million a year ago. Adjusted earnings per share (EPS) came in at $0.17, topping the $0.15 analyst consensus as compiled by LSEG. Metric Q1 Results Growth (YOY) Revenue $544.8 million 73% Monthly online revenue per subscriber $74 30% Subscribers 2.44 million 31% Adjusted EBITDA $82.2 million 109% Adjusted EPS $0.17 183% Marketing expense $231 million 77% Marketing as % of revenue 40% (600 basis points) Gross margin 76% (500 basis points) Data source: Hims & Hers Health. YOY = year over year. Looking ahead, Hims & Hers maintained its forecast for 2025 revenue to be between $2.3 billion and $2.4 billion, equal to growth of 56% to 63%. It also kept its adjusted EBITDA guidance of $295 million to $335 million. For Q3, it projected revenue of between $570 million and $590 million, and adjusted EBITDA of $60 million to $70 million. The company is starting to look toward international expansion to bolster growth. It will begin by focusing on Canada next year, while its acquisition of Zava in July will help it expand into Europe. It also anticipates entering the Latin American and Asian markets in the coming years. Hims & Hers also continues to expand into new areas. It will launch hormonal health soon, starting with lab testing. The company believes this will help it reach its targets of $6.5 billion in revenue and $1.3 billion in adjusted EBITDA in 2030. Is the stock a buy? Hims & Hers continues to be a growth engine. Even though there's been some disruption from its spat with Novo Nordisk, it is still seeing strong growth across different health categories. With the company moving into new areas, like hormonal health and longevity, and looking to expand internationally, it has a lot of growth opportunities ahead. Meanwhile, with the majority of its subscribers on personalized treatment plans, it has a pretty sticky user base. From a valuation standpoint, the stock trades at a forward price-to-earnings (P/E) ratio of around 55 based on the analyst consensus for 2025. But its forward price/earnings-to-growth ratio (PEG) is under 0.6, and stocks with PEG ratios below 1 are usually considered undervalued. Given that it operates a subscription business with high gross margins, you can also look at the stock from a price-to-sales perspective; on that front, it trades at a multiple of 5.5 times 2025 analyst estimates. Overall, I'd say, based on the type of business the company is in, that it's still reasonably priced. However, it's still a volatile stock that carries some risk depending on what happens in the weight loss segment. Still, I really like its international opportunity, and think Hims & Hers Health could have solid long-term upside from here. Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The Motley Fool Stock Advisor analyst team just identified what they believe are the for investors to buy now… and Hims & Hers Health wasn't one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when Netflix made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, you'd have $653,427!* Or when Nvidia made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, you'd have $1,119,863!* Now, it's worth noting Stock Advisor's total average return is 1,060% — a market-crushing outperformance compared to 182% for the S&P 500. Don't miss out on the latest top 10 list, available when you join Stock Advisor. See the 10 stocks » *Stock Advisor returns as of August 4, 2025 Geoffrey Seiler has no position in any of the stocks mentioned. The Motley Fool has positions in and recommends Hims & Hers Health. The Motley Fool recommends Novo Nordisk. The Motley Fool has a disclosure policy. Hims & Hers Shares Plunge. Is This a Buying Opportunity or Should Investors Run for the Hills? was originally published by The Motley Fool 登入存取你的投資組合

Associated Press
an hour ago
- Associated Press
New to The Street to Air Show #683 on Bloomberg, Featuring BioVie, FLOKI, PetVivo, and NRx Pharmaceuticals
NEW YORK CITY, NY / ACCESS Newswire / August 9, 2025 / New to The Street, one of the nation's longest-running business television brands, will broadcast Show #683 on Bloomberg today at 6:30 PM EST. This week's episode features four dynamic companies making waves in healthcare, biotech, blockchain gaming, and sports partnerships: BioVie Inc., FLOKI, PetVivo Holdings, Inc., and NRx Pharmaceuticals, Inc. The program, airing as sponsored programming, will also mark the television commercial debut of FLOKI, introducing the fastest-growing Valhalla Game to Bloomberg's national audience. Pedro Vidal, Chief Relationship Officer of FLOKI, discusses how the FLOKI Trading Bot has become the leader on the BNB Chain, giving traders advanced, user-friendly tools to maximize opportunities in the crypto market. Vidal also highlights the Valhalla Game's explosive success, where assets acquired in-game can be used in the real world - a groundbreaking integration of gaming and blockchain utility. Gamers are already winning Vera tokens, with over 100,000 Veras minted to date. For more information, visit and Jonathan Javitt, Founder, Chairman, and CEO of NRx Pharmaceuticals (NASDAQ:NRXP), discusses the Company's recent Citizen Petition to the U.S. Food and Drug Administration (FDA) seeking the removal of benzethonium chloride from all forms of ketamine sold in the United States. Benzethonium chloride, a preservative with known toxicity, is no longer allowed in hand cleansers, topical antiseptics, and many ophthalmic products. NRx has developed a preservative-free ketamine formulation with three-year stability, filed a supporting patent, and is pursuing FDA approval, including a potential labeled indication for treating suicidal depression under the FDA Commissioner's National Priority Voucher Program. Cuong Do, President and CEO of BioVie Inc. (NASDAQ:BIVI), provides an update on two ongoing Phase 3 clinical trials for Bezisterim. The first trial targets newly diagnosed Parkinson's patients entering therapy for the first time - potentially making Bezisterim the first new therapy for Parkinson's disease in more than 50 years. The second trial focuses on long COVID, specifically how Bezisterim may alleviate brain fog and fatigue, conditions affecting an estimated 17 million Americans. Both trials are expected to deliver top-line data in the first half of 2026. John Lai, CEO of PetVivo Holdings, Inc. (NASDAQ:PETV), joins Chase Chamberlin, Managing Partner at Commonwealth, to discuss their strategic partnership in the thoroughbred horse racing industry. Together, they aim to advance equine wellness by introducing PetVivo's innovative SPRYNG™ with OsteoCushion™ Technology into elite racing circles, offering a natural solution to maintain joint health in performance horses. About New to The Street For over 16 years, New to The Street has broadcast weekly as sponsored programming on Bloomberg Television and Fox Business, conducting more than 2,000 interviews with leaders from public and private companies. The brand operates the largest and fastest-growing digital business channel, New to The Street TV on YouTube, with over 3.16 million subscribers, delivering all-business, no-ads content. As a complete media ecosystem, New to The Street combines long-form television interviews, short-form TV commercials, iconic outdoor billboards, and the largest digital business platform to deliver predictable media for companies seeking to share their stories with investors, customers, and global audiences. For more information about upcoming episodes and featured companies, visit: Media Contact: Grace Bongiorno New to The Street [email protected] SOURCE: New to The Street press release
Yahoo
2 hours ago
- Yahoo
KCSO Deputy Gets Help with Cancer and Home Repairs
Kern County Sheriff's Deputy Jasmine Francisco is currently battling cancer while also facing unexpected financial hardship after discovering black mold in the home she had just purchased for her daughters. Solve the daily Crossword